Navigating EU HTA: Your Roadmap to Success Ep. 3

Unlocking Success with Joint Scientific Consultation (JSC): Crucial Considerations

We are excited to introduce the third episode in our new series of short videos dedicated to exploring the intricacies and challenges of navigating the EU Health Technology Assessment (HTA) Regulation. As we head towards the end of Q2 2025, stakeholders across the healthcare spectrum have been adapting to the significant changes brought about by the application of the EU HTA Regulation.

In this episode, we examine the Joint Scientific Consultation (JSC) under the new regulation and its strategic significance for medical device developers. With the new request window for JSC applications running from June 2 – 30, we outline when to apply, what selection criteria to be aware of, and how to weigh JSC against national advice options.

But this is just the beginning. Stay tuned for more bite-sized episodes where we will continue to share insights, practical advice, and success stories to help you navigate the evolving landscape of EU HTA.

You can also find out more information and advice in our recent article “Riding the First JSC Wave: Why should medical device developers take part?”.